Latest news with #YaleUniversitySchoolofMedicine
Yahoo
2 days ago
- Health
- Yahoo
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
The Academy of Scholars Symposium and Elmezzi Graduate School Commencement celebrate and spotlight the importance of translational biomedical research MANHASSET, N.Y., June 03, 2025--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. "The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration," said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. "The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies." Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. "Physician-scientists produce the innovations and discoveries that make a healthier world," said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. "Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics." To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on Contacts Julianne Mosher Allen516-880-4824jmosherallen@ Sign in to access your portfolio
Business Wire
2 days ago
- Health
- Business Wire
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
MANHASSET, N.Y.--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8 th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. 'The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration,' said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. 'The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies.' Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. 'Physician-scientists produce the innovations and discoveries that make a healthier world,' said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics.' To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
Medscape
4 days ago
- Health
- Medscape
AI Algorithm Predicts Transfusion Need in Acute GI Bleeds
SAN DIEGO — A novel generative artificial intelligence (AI) framework known as trajectory flow matching (TFM) can predict the need for red blood cell transfusion and mortality risk in intensive care unit (ICU) patients with acute gastrointestinal (GI) bleeding, researchers reported at Digestive Disease Week (DDW) 2025. Acute GI bleeding is the most common cause of digestive disease–related hospitalization, with an estimated 500,000 hospital admissions annually. It's known that predicting the need for red blood cell transfusion in the first 24 hours may improve resuscitation and decrease both morbidity and mortality. However, an existing clinical score known as the Rockall Score does not perform well for predicting mortality, Xi (Nicole) Zhang, an MD-PhD student at McGill University, Montreal, Quebec, Canada, told attendees at DDW. With an area under the curve of 0.65-0.75, better prediction is needed, Zhang said, whose coresearchers included Dennis Shung, MD, MHS, PhD, assistant professor of medicine and director of Applied Artificial Intelligence at Yale University School of Medicine, New Haven, Connecticut. 'We'd like to predict multiple outcomes in addition to mortality,' said Zhang, who is also a student at the Mila-Quebec Artificial Intelligence Institute. As a result, the researchers turned to the TFM approach, applying it to ICU patients with acute GI bleeding to predict both the need for transfusion and in-hospital mortality risk. The all-cause mortality rate is up to 11%, according to a 2020 study by James Y. W. Lau, MD, and colleagues. The rebleeding rate of nonvariceal upper GI bleeds is up to 10.4%. Zhang said the rebleeding rate for variceal upper gastrointestinal bleeding is up to 65%. The AI method the researchers used outperformed a standard deep learning model at predicting the need for transfusion and estimating mortality risk. Defining the AI Framework 'Probabilistic flow matching is a class of generative artificial intelligence that learns how a simple distribution becomes a more complex distribution with ordinary differential equations,' Zhang told Medscape Medical News. 'For example, if you had a few lines and shapes you could learn how it could become a detailed portrait of a face. In our case, we start with a few blood pressure and heart rate measurements and learn the pattern of blood pressures and heart rates over time, particularly if they reflect clinical deterioration with hemodynamic instability.' Another way to think about the underlying algorithm, Zhang said, is to think about a river with boats where the river flow determines where the boats end up. 'We are trying to direct the boat to the correct dock by adjusting the flow of water in the canal. In this case we are mapping the distribution with the first few data points to the distribution with the entire patient trajectory.' The information gained, she said, could be helpful in timing endoscopic evaluation or allocating red blood cell products for emergent transfusion. Study Details The researchers evaluated a cohort of 2602 patients admitted to the ICU, identified from the publicly available MIMIC-III database. They divided the patients into a training set of 2342 patients and an internal validation set of 260 patients. Input variables were severe liver disease comorbidity, administration of vasopressor medications, mean arterial blood pressure, and heart rate over the first 24 hours. Excluded was hemoglobin, since the point was to test the trajectory of hemodynamic parameters independent of hemoglobin thresholds used to guide red blood cell transfusion. The outcome measures were administration of packed red blood cell transfusion within 24 hours and all-cause hospital mortality. The TFM was more accurate than a standard deep learning model in predicting red blood cell transfusion, with an accuracy of 93.6% vs 43.2%; P ≤ .001. It was also more accurate at predicting all-cause in-hospital mortality, with an accuracy of 89.5% vs 42.5%, P = .01. The researchers concluded that the TFM approach was able to predict the hemodynamic trajectories of patients with acute GI bleeding defined as deviation and outperformed the baseline from the measured mean arterial pressure and heart rate. Expert Perspective 'This is an exciting proof-of-concept study that shows generative AI methods may be applied to complex datasets in order to improve on our current predictive models and improve patient care,' said Jeremy Glissen Brown, MD, MSc, an assistant professor of medicine and a practicing gastroenterologist at Duke University who has published research on the use of AI in clinical practice. He reviewed the study for Medscape Medical News but was not involved in the research. 'Future work will likely look into the implementation of a version of this model on real-time data.' He added: 'We are at an exciting inflection point in predictive models within GI and clinical medicine. Predictive models based on deep learning and generative AI hold the promise of improving how we predict and treat disease states, but the excitement being generated with studies such as this needs to be balanced with the trade-offs inherent to the current paradigm of deep learning and generative models compared to more traditional regression-based models. These include many of the same 'black box' explainability questions that have risen in the age of convolutional neural networks as well as some method-specific questions due to the continuous and implicit nature of TFM.' Elaborating on that, Glissen Brown said: 'TFM, like many deep learning techniques, raises concerns about explainability that we've long seen with convolutional neural networks — the 'black box' problem, where it's difficult to interpret exactly how and why the model arrives at a particular decision. But TFM also introduces unique challenges due to its continuous and implicit formulation. Since it often learns flows without explicitly defining intermediate representations or steps, it can be harder to trace the logic or pathways it uses to connect inputs to outputs. This makes standard interpretability tools less effective and calls for new techniques tailored to these continuous architectures.' 'This approach could have a real clinical impact,' said Robert Hirten, MD, associate professor of medicine and artificial intelligence, Icahn School of Medicine at Mount Sinai, New York City, who also reviewed the study. 'Accurately predicting transfusion needs and mortality risk in real time could support earlier, more targeted interventions for high-risk patients. While these findings still need to be validated in prospective studies, it could enhance ICU decision-making and resource allocation.' 'For the practicing gastroenterologist, we envision this system could help them figure out when to perform endoscopy in a patient admitted with acute gastrointestinal bleeding in the ICU at very high risk of exsanguination,' Zhang told Medscape Medical News. The approach, the researchers said, will be useful in identifying unique patient characteristics, make possible the identification of high-risk patients and lead to more personalized medicine. Hirten, Zhang, and Shung had no disclosures. Glissen Brown reported consulting relationships with Medtronic, OdinVision, Doximity, and Olympus.
Yahoo
25-04-2025
- Health
- Yahoo
National Infertility Week: What to know
CONNECTICUT, Conn. (WTNH) — Infertility affects between 10-15% of couples. This week is National Infertility Week. News 8's Darren Kramer spoke with Greenwich Hospital Fertility Specialist and Yale University School of Medicine Assistant Professor Dr. Nora Miller. Hartford HealthCare hosts 'Cuts of Kindness' Watch the full interview above. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
